Medium impact
Ranibizumab (Lucentis®); Ranibizumab-nuna [Byooviz™]; Ranibizumab-eqrn [Cimerli™]; Ranibizumab-leyk [Nufymco™]; Ranibizumab-hkdz [Ranluspec®]
BCBS Tennessee·Effective Oct 31, 2026
HCPCS J2780 is officially defined as "Injection, ranitidine hydrochloride, 25 mg." HCPCS J2780 is referenced in 1 tracked payer policy change from BCBS Tennessee. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J2780 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.